Kane Biotech Inc.
KNE.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -69.31% | -92.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -69.31% | -92.97% | |||
| Cost of Revenue | -81.36% | -79.41% | |||
| Gross Profit | 88.75% | -211.15% | |||
| SG&A Expenses | 172.18% | -84.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 82.72% | -80.00% | |||
| Operating Income | -98.19% | 75.39% | |||
| Income Before Tax | -75.07% | 70.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -75.07% | 70.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -75.07% | 70.33% | |||
| EBIT | -98.19% | 75.39% | |||
| EBITDA | -95.53% | 79.22% | |||
| EPS Basic | 13.33% | 73.68% | |||
| Normalized Basic EPS | 20.00% | 71.43% | |||
| EPS Diluted | 13.33% | 73.68% | |||
| Normalized Diluted EPS | 11.11% | 74.29% | |||
| Average Basic Shares Outstanding | 108.04% | 8.64% | |||
| Average Diluted Shares Outstanding | 87.89% | 20.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||